DE69519921T2 - Imidazolidin-derivate und ihre verwendung - Google Patents

Imidazolidin-derivate und ihre verwendung

Info

Publication number
DE69519921T2
DE69519921T2 DE69519921T DE69519921T DE69519921T2 DE 69519921 T2 DE69519921 T2 DE 69519921T2 DE 69519921 T DE69519921 T DE 69519921T DE 69519921 T DE69519921 T DE 69519921T DE 69519921 T2 DE69519921 T2 DE 69519921T2
Authority
DE
Germany
Prior art keywords
groups
group
alkyl
esterified
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69519921T
Other languages
English (en)
Other versions
DE69519921D1 (de
Inventor
Harukazu Fukami
Motoo Sumida
Shinjiro Niwata
Saki Kakutani
Masayuki Saitoh
Hiroshi Shibata
Yoshinobu Kiso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of DE69519921D1 publication Critical patent/DE69519921D1/de
Application granted granted Critical
Publication of DE69519921T2 publication Critical patent/DE69519921T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/80Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86Oxygen and sulfur atoms, e.g. thiohydantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DE69519921T 1994-07-29 1995-07-26 Imidazolidin-derivate und ihre verwendung Expired - Fee Related DE69519921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20786794 1994-07-29
JP33370694 1994-12-07
PCT/JP1995/001485 WO1996004248A1 (fr) 1994-07-29 1995-07-26 Derives d'imidazolidine et son utilisation

Publications (2)

Publication Number Publication Date
DE69519921D1 DE69519921D1 (de) 2001-02-22
DE69519921T2 true DE69519921T2 (de) 2001-06-13

Family

ID=26516513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519921T Expired - Fee Related DE69519921T2 (de) 1994-07-29 1995-07-26 Imidazolidin-derivate und ihre verwendung

Country Status (7)

Country Link
US (1) US5691335A (de)
EP (1) EP0721944B1 (de)
AT (1) ATE198743T1 (de)
AU (1) AU3086095A (de)
DE (1) DE69519921T2 (de)
ES (1) ES2155134T3 (de)
WO (1) WO1996004248A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912261A (en) * 1994-12-20 1999-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Carboxyalkyl heterocyclic derivatives
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
JPH10182460A (ja) * 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd 3−デオキシグルコソン生成阻害剤
US20050267148A1 (en) * 1998-07-15 2005-12-01 Teijin Limited Benzimidazole derivative
JP3923255B2 (ja) * 1998-07-15 2007-05-30 帝人株式会社 チオベンズイミダゾール誘導体
KR100381214B1 (ko) * 1998-08-10 2003-09-22 주식회사 엘지생명과학 항암제로유용한이미다졸리딘-2,4-디온유도체및그의제조방법
CA2341195A1 (en) * 1998-08-20 2000-03-02 Mitsunori Waki Prophylactic or therapeutic composition for ocular circulation disorders
HUP0103387A3 (en) * 1998-08-21 2002-07-29 Daiichi Asubio Pharma Co Ltd Quinazoline derivatives preparation thereof, medicament containing them and their intermediates
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
WO2000032587A1 (fr) * 1998-12-01 2000-06-08 Meiji Seika Kaisha, Ltd. Substances sf2809-i, ii, iii, iv, v et vi presentant une activite d'inhibition de la chymase
EP1224945A4 (de) * 1999-10-25 2004-08-18 Senju Pharma Co Mittel zur linderung der ziliarmuskelspannung
EP1142586B1 (de) 1999-11-01 2007-04-25 Daiichi Asubio Pharma Co., Ltd. Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
US6300503B1 (en) * 1999-12-17 2001-10-09 Dixie Chemical Company Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
DE60121695T2 (de) * 2000-02-22 2007-08-30 Daiichi Asubio Pharma Co., Ltd. Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
CA2368366A1 (en) 2000-02-22 2001-08-30 Suntory Limited Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient
EP1174151B1 (de) 2000-02-22 2007-01-24 Daiichi Asubio Pharma Co., Ltd. Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
US6919365B2 (en) * 2001-04-11 2005-07-19 Senju Pharmaceutical Co., Ltd. Imidazolidinedione derivatives and use thereof as drugs
PL373234A1 (en) * 2002-07-30 2005-08-22 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure
US20060025589A1 (en) * 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2845384B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845383B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
JP4702054B2 (ja) 2003-05-09 2011-06-15 東レ株式会社 増強剤
US7361767B2 (en) * 2003-11-14 2008-04-22 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en) 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7544756B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
DK2656842T3 (en) 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
US8501749B2 (en) 2009-01-30 2013-08-06 Boehringer Ingelheim International Gmbh Azaquinazolinediones chymase inhibitors
MX355915B (es) 2010-02-16 2018-05-04 Aragon Pharmaceuticals Inc Moduladores del receptor de androgenos y usos de los mismos.
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10508104B2 (en) * 2016-06-14 2019-12-17 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
CN109641843B (zh) * 2016-06-14 2022-07-19 百时美施贵宝公司 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮
US11236053B2 (en) 2017-07-26 2022-02-01 Emory University NADPH oxidase inhibitors and uses thereof
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207391B (de) * 1962-05-30 1965-12-23 Degussa Verfahren zur Herstellung von 3-Benzoyl-5, 5-dimethylhydantoinen
US4166124A (en) * 1970-05-15 1979-08-28 U.S. Philips Corporation Insecticidal 2,6-dihalobenzoyl urea derivatives
JPS5371073A (en) * 1976-12-03 1978-06-24 Sumitomo Chem Co Ltd 1-cyclic alkyl carbonyl-3(3,5-dihalogenophenyl)hydantoin derivs., process fo r their preparation and fungicides for agriculture and horti culture contg. the same as active constituents
JPS5855468A (ja) * 1981-09-25 1983-04-01 Sumitomo Chem Co Ltd 5−クロロヒダントイン誘導体、その製造法およびそれを有効成分として含有する殺虫剤
US4474796A (en) * 1983-02-04 1984-10-02 Sumitomo Chemical Company, Limited Insecticidal substituted hydantoins
JPH068281B2 (ja) * 1985-09-19 1994-02-02 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤

Also Published As

Publication number Publication date
EP0721944B1 (de) 2001-01-17
DE69519921D1 (de) 2001-02-22
US5691335A (en) 1997-11-25
EP0721944A1 (de) 1996-07-17
EP0721944A4 (de) 1997-01-02
ES2155134T3 (es) 2001-05-01
AU3086095A (en) 1996-03-04
WO1996004248A1 (fr) 1996-02-15
ATE198743T1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
DE69519921T2 (de) Imidazolidin-derivate und ihre verwendung
ATE225770T1 (de) Difluoroprostaglandin-derivate und ihre anwendung
EP1070710A3 (de) Dithiolan Derivate, deren Herstellung und deren therapeutischer Wirkung
IL184539A (en) The heteroaryl sulfonamide compounds, their preparations and their uses
ATE376998T1 (de) 1,2-diphenylpyrrol-derivate, ihre herstellung und therapeutische verwendung
EP0795548A4 (de) Chinazozin derivate und deren verwendung
NO174050C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive benzopyranforbindelser
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
EP0549796A4 (en) Diphenylpiperazine derivative and drug for circulatory organ containing the same
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
BRPI0408675A (pt) derivados de talidomida solúveis em água
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
DE69713648T2 (de) Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten
HUP9904498A2 (hu) 17-Difluor-metilén-ösztra-triének alkalmazása lipoprotein(A) plazmaszintek csökkentésére
PT868428E (pt) Derivados de acido fosfonico possuindo actividade inibidora da metalopeptidase
DE69722630D1 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen
DE3782229T2 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAICHI SUNTORY PHARMA CO., LTD., TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI ASUBIO PHARMA CO., LTD., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee